NASDAQ:MEDP - Medpace Stock Price, Forecast & News

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) announced its earnings results on Tuesday, October, 29th. The company reported $0.71 EPS for the quarter, meeting the consensus estimate of $0.71. The company had revenue of $216.20 million for the quarter, compared to analyst estimates of $217.14 million. Medpace had a return on equity of 17.06% and a net margin of 11.35%. The firm's revenue for the quarter was up 20.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 EPS. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Medpace.

Medpace will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace updated its FY19 earnings guidance on Monday, October, 28th. The company provided earnings per share (EPS) guidance of $2.85-2.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.91. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $857.27 million.

4 brokerages have issued 12 month price targets for Medpace's shares. Their forecasts range from $62.00 to $85.00. On average, they anticipate Medpace's stock price to reach $74.67 in the next year. This suggests that the stock has a possible downside of 18.1%. View Analyst Price Targets for Medpace.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Media stories about MEDP stock have been trending extremely negative on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Medpace.

Medpace saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 2,460,000 shares, an increase of 5.1% from the November 28th total of 2,340,000 shares. Based on an average trading volume of 307,200 shares, the short-interest ratio is presently 8.0 days. Approximately 8.9% of the company's stock are sold short. View Medpace's Current Options Chain.

Some companies that are related to Medpace include EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Paycom Software (PAYC), Adobe (ADBE), Paypal (PYPL), Arista Networks (ANET), Veeva Systems (VEEV), Verizon Communications (VZ) and Cyberark Software (CYBR).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.52%), Norris Perne & French LLP MI (0.31%), Scout Investments Inc. (0.27%), McGuire Investment Group LLC (0.11%), State of Alaska Department of Revenue (0.06%) and Convergence Investment Partners LLC (0.04%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Assenagon Asset Management S.A., Tributary Capital Management LLC, Convergence Investment Partners LLC, Scout Investments Inc., Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was acquired by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC, Norris Perne & French LLP MI, Exchange Traded Concepts LLC, Vigilant Capital Management LLC, First National Bank of Omaha and Campbell Newman Asset Management Inc.. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $91.17.

Medpace has a market capitalization of $3.28 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]